Oncology – Lung
NICE Updated Guideline | Diagnosis and management of lung cancer
4 Aug, 2023 | 12:05h | UTCLung cancer: diagnosis and management – National Institute for Health and Care Excellence
ASCO Guideline Update | Management of Stage III Non–Small-Cell Lung Cancer
4 Aug, 2023 | 12:03h | UTC
RCT | Lazertinib offers 20.6-month of median PFS in EGFR-mutated NSCLC vs 9.7 months with gefitinib
2 Aug, 2023 | 13:55h | UTC
Phase 2 Trial | The addition of immunotherapy to stereotactic ablative radiotherapy may enhance EFS in early-stage NSCLC
25 Jul, 2023 | 13:36h | UTCStereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial – The Lancet (link to abstract – $ for full-text)
Systematic Review | Platinum doublet therapy outperforms non-platinum for advanced NSCLC, performance status 2 patients
20 Jul, 2023 | 10:56h | UTC
RCT | Atezolizumab in platinum-ineligible NSCLC elevates median survival to 10.3 months vs. 9.2 months with chemotherapy
10 Jul, 2023 | 13:33h | UTCFirst-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study – The Lancet (link to abstract – $ for full-text)
News Release: Immunotherapy for ‘difficult to treat’ lung cancer patients improves long-term survival – University College London
RCT | Perioperative nivolumab plus chemotherapy increases pathological response vs. chemotherapy alone in stage III NSCLC
10 Jul, 2023 | 13:27h | UTCPerioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Addition of Neoadjuvant Nivolumab to Platinum-Based Chemotherapy in Stage III NSCLC – The ASCO Post
Commentary on Twitter
Original Article: Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer https://t.co/DCcs0tkyPN #oncology pic.twitter.com/0zG9SUbqQj
— NEJM (@NEJM) June 30, 2023
Perspective | Early-stage lung cancer: using circulating tumor DNA to get personal
26 Jun, 2023 | 00:38h | UTCEarly-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal – Journal of Clinical Oncology
Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions
26 Jun, 2023 | 00:31h | UTC
Cohort Study | Stopping immunotherapy in patients that are progression-free at 2 years seems feasible in advanced NSCLC
21 Jun, 2023 | 13:19h | UTCAssociation Between Duration of Immunotherapy and Overall Survival in Advanced Non–Small Cell Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Study of patients with #NSCLC showed no survival difference between 2-yr fixed duration vs indefinite #immunotherapy, suggesting that IO can be d/c at 2 yrs. @PennCancer @flatironhealth @lovasunMD @Ron_cology @CharuAggarwalMD #ASCO23 https://t.co/EWyneghc8a pic.twitter.com/HkyIwwtJiM
— JAMA Oncology (@JAMAOnc) June 4, 2023
RCT | Perioperative pembrolizumab improves pathological outcomes, event-free survival in early-stage NSCLC
6 Jun, 2023 | 14:36h | UTCPerioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Presented at #ASCO23: In the KEYNOTE-671 trial, pts with resectable lung cancer were assigned to neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo. Two-year event-free survival was 62.4% with pembrolizumab & 40.6% with placebo.
— NEJM (@NEJM) June 3, 2023
RCT | Befotertinib tops Icotinib in NSCLC progression-free survival, but increases serious adverse events
6 Jun, 2023 | 14:13h | UTCBefotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
RCT | Osimertinib improves overall survival in resected EGFR-mutated NSCLC, but validity of control group questioned on social media
5 Jun, 2023 | 13:46h | UTCOverall Survival with Osimertinib in Resected EGFR-Mutated NSCLC – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter by Dr. Vinay Prasad (recommended – click to see the video)
Here is the REAL @Plenary_Session on #ADAURA #ASCO23 #ASCO2023
38.5% of people who had recurrence got OSI (very low!)
That just isn't good enough
Brain staging is suboptimal= occult met disease
Would you let your mother be on the control arm and not get OSI on progression? pic.twitter.com/CU3jtrvFOj— Vinay Prasad MD MPH (@VPrasadMDMPH) June 5, 2023
RCT | Gefitinib plus chemotherapy vs. Gefitinib alone in untreated EGFR-mutant NSCLC with brain metastases
16 May, 2023 | 14:30h | UTC
Commentary on Twitter
RCT: In patients with untreated EGFR-mutated non-small cell lung cancer with brain metastases, gefitinib + chemo improved survival and PFS vs gefitinib, with manageable adverse events, and may be a viable first-line treatment. #NSCLC https://t.co/Oe6zHYVsPV pic.twitter.com/oUvs12pYS7
— JAMA Network Open (@JAMANetworkOpen) February 9, 2023
Clinical Trial Update | Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer
16 May, 2023 | 14:25h | UTCCommentaries:
Original Study: Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer – New England Journal of Medicine
Post-pneumonectomy syndrome: a systematic review of the current evidence and treatment options
15 May, 2023 | 12:45h | UTC
ASTRO/ESTRO Guideline | Treatment of oligometastatic non-small cell lung cancer
4 May, 2023 | 13:44h | UTC
Commentary on Twitter
ASTRO & ESTRO partnered to issue the first guideline on local therapy for oligometastatic lung cancer, out today in #PracticalRadOnc https://t.co/ZiM2RWX394 @ESTRO_RT @IyengarPuneeth @Mat_Guc pic.twitter.com/5DV3fRdn1o
— ASTRO (@ASTRO_org) April 25, 2023
Clinical Trial Update | Adjuvant Osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer
4 May, 2023 | 13:33h | UTCOriginal Study: Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer – New England Journal of Medicine
News Release: Trial shows significant disease-free survival for patients diagnosed with non-small cell lung cancer – Yale University
RCT | Endosonography with or without confirmatory mediastinoscopy for resectable lung cancer
26 Apr, 2023 | 13:56h | UTC
Updated ADAURA trial results | Adjuvant Osimertinib improves disease-free survival in resected EGFR-mutated NSCLC
5 Apr, 2023 | 13:21h | UTCNews Release: Trial Shows Significant Disease-free Survival for Patients Diagnosed With Non-small Cell Lung Cancer – Yale School of Medicine
Expanding Organ Usage: UK study finds organs from patients with a primary brain tumor are a viable option
27 Mar, 2023 | 13:27h | UTCSummary: A national cohort study in the UK investigated the risk of cancer transmission from deceased donors with primary brain tumors to organ recipients. The study found no cases of brain tumor transmission among 778 transplants from 282 donors with primary brain tumors, including 262 from donors with high-grade tumors. Organ transplant survival was equivalent to that in matched controls, and some organs from donors with high-grade tumors were less likely to be transplanted.
The results suggest that the risk of cancer transmission in transplants from deceased donors with primary brain tumors is lower than previously thought. Furthermore, the study indicated that donors with brain tumors provided good-quality organs with favorable risk markers and excellent transplant outcomes. Some organs from donors with high-grade tumors were underutilized, indicating a possible aversion by transplant clinicians or patients to use these organs.
These findings imply that it may be possible to safely expand organ usage from donors with primary brain tumors without negatively impacting outcomes, potentially benefiting many patients waiting for a transplant. Although this might lead to a slight rise in transplant numbers in the UK, the findings may hold particular significance for nations with stricter guidelines, such as the United States. The study’s findings can help transplant clinicians discuss the risks and benefits of accepting organ offers from such donors.
RCT | Sotorasib vs. docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation
20 Mar, 2023 | 13:10h | UTCSotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
Docetaxel is the recommended treatment for non-small-cell lung cancer (NSCLC) at disease progression, but it has shown modest clinical benefit.
The CodeBreaK 200 trial compares the KRAS inhibitor sotorasib with docetaxel in patients with advanced NSCLC.https://t.co/Sk7Rk1lAl2
— The Lancet (@TheLancet) March 9, 2023
Practice Guide | Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing
9 Mar, 2023 | 14:04h | UTC
RCT | Effects of a respiratory distress symptom intervention for lung cancer breathlessness–cough–fatigue symptom cluster
2 Mar, 2023 | 12:51h | UTC
M-A | Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer
14 Feb, 2023 | 10:34h | UTC